国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
International Journal of Traditional Chinese Medicine
2015年
11期
991-993
,共3页
王彬%李小园%刘洋%张凤云%王靖
王彬%李小園%劉洋%張鳳雲%王靖
왕빈%리소완%류양%장봉운%왕정
肺肿瘤%红归胶囊%抗肿瘤联合化疗方案%生活质量%疗效比较研究
肺腫瘤%紅歸膠囊%抗腫瘤聯閤化療方案%生活質量%療效比較研究
폐종류%홍귀효낭%항종류연합화료방안%생활질량%료효비교연구
Lung neoplasms%Honggui capsule%Antineoplastic combined chemotherapy protocols%Quality of life%Comparative effectiveness research
目的:评价红归胶囊联合化疗治疗肺癌的临床疗效。方法将符合入选标准的肺癌患者61例,采用随机数字表法分为观察组30例和对照组31例,对照组采用化疗,治疗在对照组基础上加服红归胶囊,21 d 为1个疗程,共治疗3个疗程。比较2组治疗后肿瘤客观疗效、生活质量改善情况、中医症状改善情况及毒副反应发生率。结果治疗后,治疗组肿瘤缓解率[26.7%(8/30)比3.2%(1/31),χ2=4.927]、卡氏评分提高率[23.3%(7/30)比3.3%(1/31),χ2=5.410]与对照组比较,差异均有统计学意义(P<0.05);治疗组显著改善4例(13.3%),对照组未见显著改善患者。2组显著改善率比较,差异有统计学意义(χ2=4.423、P=0.035);治疗期间,治疗组骨髓抑制发生率[33.3%(10/30)比58.1%(18/31),χ2=4.778]、消化道反应发生率[16.7%(5/30)比58.1%(18/31),χ2=11.124]与对照组比较,差异均有统计学意义(P<0.05)。结论红归胶囊配合化疗可改善肺癌患者的临床症状,提高疗效,减轻化疗的毒副作用。
目的:評價紅歸膠囊聯閤化療治療肺癌的臨床療效。方法將符閤入選標準的肺癌患者61例,採用隨機數字錶法分為觀察組30例和對照組31例,對照組採用化療,治療在對照組基礎上加服紅歸膠囊,21 d 為1箇療程,共治療3箇療程。比較2組治療後腫瘤客觀療效、生活質量改善情況、中醫癥狀改善情況及毒副反應髮生率。結果治療後,治療組腫瘤緩解率[26.7%(8/30)比3.2%(1/31),χ2=4.927]、卡氏評分提高率[23.3%(7/30)比3.3%(1/31),χ2=5.410]與對照組比較,差異均有統計學意義(P<0.05);治療組顯著改善4例(13.3%),對照組未見顯著改善患者。2組顯著改善率比較,差異有統計學意義(χ2=4.423、P=0.035);治療期間,治療組骨髓抑製髮生率[33.3%(10/30)比58.1%(18/31),χ2=4.778]、消化道反應髮生率[16.7%(5/30)比58.1%(18/31),χ2=11.124]與對照組比較,差異均有統計學意義(P<0.05)。結論紅歸膠囊配閤化療可改善肺癌患者的臨床癥狀,提高療效,減輕化療的毒副作用。
목적:평개홍귀효낭연합화료치료폐암적림상료효。방법장부합입선표준적폐암환자61례,채용수궤수자표법분위관찰조30례화대조조31례,대조조채용화료,치료재대조조기출상가복홍귀효낭,21 d 위1개료정,공치료3개료정。비교2조치료후종류객관료효、생활질량개선정황、중의증상개선정황급독부반응발생솔。결과치료후,치료조종류완해솔[26.7%(8/30)비3.2%(1/31),χ2=4.927]、잡씨평분제고솔[23.3%(7/30)비3.3%(1/31),χ2=5.410]여대조조비교,차이균유통계학의의(P<0.05);치료조현저개선4례(13.3%),대조조미견현저개선환자。2조현저개선솔비교,차이유통계학의의(χ2=4.423、P=0.035);치료기간,치료조골수억제발생솔[33.3%(10/30)비58.1%(18/31),χ2=4.778]、소화도반응발생솔[16.7%(5/30)비58.1%(18/31),χ2=11.124]여대조조비교,차이균유통계학의의(P<0.05)。결론홍귀효낭배합화료가개선폐암환자적림상증상,제고료효,감경화료적독부작용。
Objective To observe the clinical efficacy of Honggui capsule combined with chemotherapy in the treatment of lung cancer. Methods 61 cases of lung cancer patients were randomly divided into group A of 30 cases, treated with Honggui Capsule and chemotherapy, and group B of 31 cases treated with chemotherapy only by the envelope method. After both groups were treated for 21 days, the clinical effect, life quality improvement, improvement of TCM symptoms and the incidence of toxic and side effects in 2 groups were compared. Results After treatment, there was significant difference between group A and B in the tumor response rate (26.7% vs. 3.2%; χ2=4.927, P=0.026), Karnofsky (23.3% vs. 3.3%; χ2=5.410, P=0.020), and improvement of TCM symptoms (13.3% vs. 0.0%; χ2=4.423, P=0.035). During treatment, there was significant difference between group A and B in bone marrow suppression (33.3% vs. 58.1%; χ2=4.778, P=0.029), and gastrointestinal disturbance (16.7% vs. 58.1%; χ2=11.124, P=0.001). Conclusion Honggui capsule combined with chemotherapy has an enhanced efficacy and a detoxicating effect, besides it improves clinical symptoms and reduces the side effects of chemotherapy.